Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Pediatric Infect Dis Soc ; 10(7): 757-765, 2021 Aug 17.
Article in English | MEDLINE | ID: mdl-34129032

ABSTRACT

BACKGROUND: Most pediatric coronavirus disease 2019 (COVID-19) is mild. We assessed nationally severe COVID-19, including pediatric inflammatory multisystem syndrome (PIMS), in hospitalized children. METHODS: An ongoing, prospective, national surveillance was conducted from March 2020 through March 2021, at 20 hospitals treating children <18 years across Israel (~75% of Israeli hospitals). RESULTS: Overall, 1007 cases (439 outpatients and 568 hospitalized) identified represent 0.35% of pediatric COVID-19 nationwide (n = 291 628). Of hospitalized cases, 464 (82%), 48 (8%), and 56 (10%) had mild, moderate/severe, and PIMS disease, respectively. The mean ± SD age was 5.6 ± 6.4 years. In mild, moderate/severe, and PIMS disease, 55%, 23%, and 4% of patients were <1 year old, respectively. Obesity was reported in 1%, 4%, and 13% of patients, respectively (P < .001). The most common symptom was fever in 67%, 60%, and 100%, respectively, whereas respiratory symptoms were documented in 33%, 41%, and 38% of patients, respectively. Lymphopenia was recorded in 25%, 60%, and 86% of cases, respectively. PIMS diagnosis was mainly serology-based (in 59%). Gastrointestinal symptoms, cardiovascular involvement, rash, and conjunctivitis were noted in 82%, 61%, 57%, and 34% of PIMS episodes, respectively. Elevated C-reactive protein (100%), ferritin, troponin, D-dimer, low albumin, and thrombocytopenia were common in PIMS. Echocardiography revealed pathological findings in 33% of patients. PIMS mainstay treatment included corticosteroids (77%) and intravenous immunoglobulin (53%). No mortality was recorded. CONCLUSIONS: At a national level, pediatric COVID-19 is mild, even in hospitalized cases, with only a third presenting with respiratory involvement. PIMS is rare, but necessitates a high index of suspicion, and with suitable treatment prognosis is favorable.


Subject(s)
COVID-19 , Child , Child, Hospitalized , Child, Preschool , Humans , Infant , Israel/epidemiology , Prospective Studies , SARS-CoV-2 , Systemic Inflammatory Response Syndrome
2.
Pediatr Infect Dis J ; 39(9): e270-e272, 2020 09.
Article in English | MEDLINE | ID: mdl-32658093

ABSTRACT

Among individuals who tested positive for coronavirus disease 2019, smell and taste sensations were significantly less impaired among children than among adults, in a stepwise manner. Sensory impairment was correlated with recent data of angiotensin-converting enzyme 2 expression in the corresponding age groups. This is the first report to compare sensory impairment in children and adults testing positive for coronavirus disease 2019.


Subject(s)
Coronavirus Infections/physiopathology , Hypesthesia/virology , Peptidyl-Dipeptidase A/biosynthesis , Pneumonia, Viral/physiopathology , Adolescent , Adult , Age Factors , Angiotensin-Converting Enzyme 2 , Betacoronavirus/isolation & purification , COVID-19 , Child , Child, Preschool , Coronavirus Infections/enzymology , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Humans , Hypesthesia/enzymology , Hypesthesia/physiopathology , Israel/epidemiology , Pandemics , Peptidyl-Dipeptidase A/metabolism , Pneumonia, Viral/enzymology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , SARS-CoV-2 , Smell/physiology , Taste/physiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...